Current Report Filing (8-k)
September 20 2016 - 4:16PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event
reported): September 15, 2016
NOVAVAX, INC.
(Exact name of registrant as specified
in charter)
|
|
|
|
|
Delaware
|
|
0-26770
|
|
22-2816046
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.)
|
20 Firstfield Road
Gaithersburg, Maryland 20878
(Address of Principal Executive Offices,
including Zip Code)
(240) 268-2000
(Registrant’s telephone number,
including area code)
(Former name or former
address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
¨
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Topline RSV F Vaccine Data from
Two Clinical Trials in Older Adults
On September 15,
2016, Novavax, Inc. (the “Company”) issued a press release announcing the Company’s topline data from two clinical
trials of its RSV F-protein recombinant nanoparticle vaccine candidate (RSV F Vaccine) in older adults. A copy of this press release
is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
Exhibit
No.
|
|
Description
|
|
|
|
|
99.1
|
|
Press release, dated September 15, 2016, regarding the Company’s topline RSV F Vaccine data from two clinical trials in older adults.
|
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
Novavax, Inc.
(Registrant)
|
|
|
|
|
|
|
Date: September 20, 2016
|
|
|
|
By:
|
|
/s/ John A. Herrmann III
|
|
|
|
|
|
|
|
Name:
|
|
John A. Herrmann III
|
|
|
|
|
|
|
|
Title:
|
|
Senior Vice President, General Counsel and
Corporate Secretary
|
|
EXHIBIT INDEX
Exhibit
No.
|
|
Description
|
|
|
|
|
99.1
|
|
Press release, dated September 15, 2016, regarding the Company’s topline RSV F Vaccine data from two clinical trials in older adults.
|
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Sep 2023 to Sep 2024